Influences on visit retention in clinical trials: Insights from qualitative research during the VOICE trial in Johannesburg, South Africa

BMC Women's Health

Volumn 14, Issue 1, 2014, Pages

  Magazi, Busisiwe ^a   Stadler, Jonathan ^a   Delany Moretlwe, Sinead ^a   Montgomery, Elizabeth ^b   Mathebula, Florence ^a   Hartmann, Miriam ^b   van der Straten, Ariane ^b,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV prevention; Microbicides; PrEP; South Africa; Visit retention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; FEMALE; HIV INFECTIONS; HOSPITAL MANAGEMENT; HUMAN; INFORMATION PROCESSING; PATIENT COMPLIANCE; PATIENT DROPOUTS; PSYCHOLOGY; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AFRICA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; APPOINTMENTS AND SCHEDULES; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PATIENT DROPOUTS; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOUTH AFRICA; YOUNG ADULT;

EID: 84904784967     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-14-88     Document Type: Article

References (21)

1. Mâsse B, Boily M, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol 2009, 6(5):1-8.
2. Woodsong C, MacQueen K, Amico KR, Friedland B, Gafos M, Mansoor L, Tolley E, McCormack S. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc 2013, 16(18505):1-9.
3. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 2008, 5(8):1-7.
4. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012, 26(7):F13-F19.
5. Kidd KE, Altman DG. Adherence in social context. Control Clin Trials 2000, 21(5, S1):S184-S187.
6. Ambia J, Agot K. Barriers and facilitators of adherence in user- dependent HIV prevention trials, a systematic review. International STD Research and Reviews 2013, 1(1):12-29.
7. Feldblum P, Helpern V, Lie C, Obunge O, Ogunsola F, Ampofo W, Opoku K. What predicts non-retention in microbicide trials. Contemp Clin Trials 2011, 32:512-516.
8. de Bruyn G, Hudgens MG, Sullivan PS, Duerr AC. Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 2005, 39(4):499-501.
9. United Nations UNAIDS Report on the Global AIDS Epidemic 2013, Geneva: United Nations, United Nations.
10. Chersich MF, Rees VH. Vulnerability of women in Southern Africa to infection with HIV: biological determinants and priority health sector interventions. AIDS 2008, 22(suppl 4):S1-S14.
11. Karim QA, Humphries H, Stein Z. Empowering women in human immunodeficiency virus prevention. Best Pract Res Clin Obstet Gynaecol 2012, 26:487-493.
12. Pettifor AE, Measham D, Rees H, Padian N. Sexual power and HIV risk, South Africa. Emerg Infect Dis 2004, 10(11):1996-2004.
13. Gappoo S, Montgomery ET, Gerdts C, Naidoo S, Chidanyika A, Nkala B, Ramjee G, . MIRA Team Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe. Contemp Clin Trials 2009, 30(5):411-418. MIRA Team.
14. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, Taljaard M, Piper J, Gomez K, Chirenje M. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the voice study (MTN003). Abstract#26LB. Conference of Retroviral and Opportunistic Infections 2013, Atlanta, USA: Georgia World Congress Centre.
15. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One 2014, 9(2):1-12.
16. Ware NC, Wyatt MA, Geng EH, Kaaya SF, Agbaji OO, Muyindike WR, Chalamilla G, Agaba PA. Toward an understanding of disengagement from HIV treatment and care in Sub-Saharan Africa: a qualitative study. PLoS Med 2013, 10(1):1-10.
17. Montgomery C. Making Prevention Public: The co-production of gender and technology in HIV prevention research. Soc Stud Sci 2012, 42(6):922-944.
18. McPhail C, Delany-Moretlwe S, Mayaud P. 'It's not about money, it's about my health': determinants of participation and adherence among women in an HIV-HSV 2 prevention trial in Johannesburg, South Africa. Patient Prefer Adherence 2012, 6:579-588.
19. Delany-Moretlwe S, Stadler J, Mayaud P, Rees H. Investing in the future: Lessons learned from communicating the results of HSV/HIV intervention in South Africa. Health Res Policy Syst 2011, 9(1):1-9.
20. Kunutsor S, Walley J, Katabira E, Muchuro S, Balidalwa H, Namagala E, Ikoona E. Improving clinic attendance and adherence to antiretroviral therapy through a treatment supporter intervention in Uganda: a randomized controlled trial. AIDS Behav 2011, 15:1795-1802.
21. Scott C, Walker J, White P, Lewith G. Forging convictions: The effects of active participation in a clinical trial. Soc Sci Med 2011, 72(12):2041-2048.